Sanofi India Q3 FY26 Risks

Revenue ₹1,511 Cr

EBITDA —

PAT — +4%

EBITDA Margin 21.5%

Duration 54 min

Read Time 1 min read

Financial stats pending filing verification

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Quarterly fluctuations due to inventory phasing and frozen periods may persist through FY26, obscuring underlying growth.

high · management_commentary

Aggressive discounting by competitors in certain accounts and institutional business is impacting partnership sales.

medium · analyst_question

Rapid growth of GLP-1 drugs could cannibalize insulin sales, though Soliqua (GLP-1/insulin combo) may mitigate.

medium · data_observation